论文信息 - Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577. - 字舞流文

Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577.

J. Ajani | T. Zander | A. Lièvre | S. Motoyama | G. Piessen | J. Feliciano | R. Kelly | E. Cutsem | M. Lei | K. Geboes | Samira Soleymani | H. Uronis | E. Elimova | M. Moehler | J. Kużdżał | C. Grootscholten | J. Cleary | Prianka Singh | G. Mendez | Jenny Zhang